Last reviewed · How we verify
NCT04459689: COPID19
COVID-19 in PID Survey
trial in Primary Immune Deficiency in 200 participants. Currently enrolling.
18 February 2027
Quick facts
| Lead sponsor | Imagine Institute |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 15 March 2020 |
| Primary completion | 18 February 2027 |
| Estimated completion | 18 February 2027 |
| Sites | 1 location across France |
Conditions studied
- Primary Immune Deficiency — all drugs for Primary Immune Deficiency →
- COVID — all drugs for COVID →
Sponsor
Imagine Institute
Who can join
0 and older, any sex, with Primary Immune Deficiency or COVID. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
With the emergence of SARS-CoV-2 and the COVID-19 pandemic, there is an urgent need to understand the impact of infection on immunodeficient individuals. Whilst co-morbidities (such as diabetes, cancer, arterial hypertension, heart disease...) have been documented in people infected with SARS-CoV-2, there is currently no information on the consequences and outcomes for individuals with primary immunodeficiencies (PID). Following the 1st phase of the survey (launched by Isabelle Meyts (ESID), Nizar Mahlaoui (CEREDIH \& IPOPI) and Kate Sullivan with Stuart Tangye (IUIS), that gave an idea of the number of affected PID patients and the impact of SARS-CoV-2 and directly focusing on obtaining this top level of information), we are launching the 2nd phase: "COPID19". COPID19 survey is a secured online GDPR compliant platform based in Paris (Imagine Institute). It has been approved by the Paris-Necker-Enfants malades IRB and Ethics Committee. However, this retrospective survey is designed for global distribution. Data can be entered by a health care professional (mostly clinicians) through a personal login and password. Each documenting person will have access to his/her own patients' data. COPID19 require a greater level of information than the 1st phase. The eCRF will be open to evolutions depending on progresses in our knowledge of this pandemic.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04459689
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Primary Immune Deficiency
Currently open trials in the same condition.
- NCT05321407 — COVID-19 Vaccine Responses in PIDD Subjects · active not recruiting
- NCT00246857 — Screening Protocol for Genetic Diseases of Lymphocyte Homeostasis and Programmed Cell Death · recruiting
Other Imagine Institute trials
Trials by the same sponsor.
- NCT07313098 — Longitudinal Assessment of Protein Markers in the Cerebrospinal Fluid of Patients With Central Nervous System Involvemen · not yet recruiting
- NCT07422454 — FACE.S-4-KIDS : A Deep Phenotyping Database of Craniofacial Anomalies During Development With 4 Pilot Projects · recruiting
- NCT06219421 — Automatic Phenotyping of Patients on 2D Photography · recruiting
- NCT06186856 — Epidemiological Data on Mast Cell Pathologies in France · recruiting
- NCT06380192 — Developmental and Epileptic Encephalopathy of Genetic Etiology: Natural History Through Reuse of Clinical Data · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04459689 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Imagine Institute
- Last refreshed: 5 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04459689.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing